Effectiveness of Pregabalin Compared to Duloxetine in Diabetic Peripheral Neuropathic Pain: An Observational Study.


Journal

The Journal of the Association of Physicians of India
ISSN: 0004-5772
Titre abrégé: J Assoc Physicians India
Pays: India
ID NLM: 7505585

Informations de publication

Date de publication:
Nov 2019
Historique:
entrez: 4 12 2019
pubmed: 4 12 2019
medline: 19 12 2019
Statut: ppublish

Résumé

Neuropathy is a comorbid complication of diabetes and Pregabalin and Duloxetine are the two most common drugs used for the treatment of neuropathic pain. To determine the effectiveness and side effects of Pregabalin and Duloxetine in patients with diabetic peripheral neuropathic pain. This prospective observational study was conducted at Max Super Speciality Hospital. Patients attending the endocrinology department, above 18 years of age who were prescribed with Pregabalin or Duloxetine were screened and included in this study. The data was collected for all study participants using a specially designed case record form by conducting personal interviews. SF-MPQ, Mc-Gill, NRS and DN-4 questionnaires were used to assess the extent of pain and the side-effects associated with the drugs. Based on the responses from the Numerical Rating Scale and McGill Pain Questionnaire, Pregabalin was seen to be less effective compared to Duloxetine. The only side effect observed with Pregabalin was drowsiness, which was observed in 4% cases at 50 mg dose whereas those reported with Duloxetine were drowsiness (22.2% at 20 mg and 33.3% at 30 mg), vomiting (11.1% at 20mg and 30mg), headache (11.1% at 20 mg and 30 mg), and dizziness (0% at 20mg and 11.1% at 30 mg). Pregabalin has a better safety profile and tolerability compared to Duloxetine but the latter is more effective in treating Diabetic Peripheral Neuropathic Pain. However, further studies with a larger sample size and longer duration are required to be conducted for finding the effectiveness of these drugs, specifically in the Indian population.

Identifiants

pubmed: 31793266

Substances chimiques

Analgesics 0
Pregabalin 55JG375S6M
Duloxetine Hydrochloride 9044SC542W

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-36

Informations de copyright

© Journal of the Association of Physicians of India 2011.

Auteurs

Sujeet Jha (S)

Institute of Endocrinology, Diabetes and Metabolism, Max Healthcare Institute Ltd., New Delhi.

Om Prakash Sahani (OP)

Institute of Endocrinology, Diabetes and Metabolism, Max Healthcare Institute Ltd., New Delhi.

Samreen Siddiqui (S)

Institute of Endocrinology, Diabetes and Metabolism, Max Healthcare Institute Ltd., New Delhi.

Manoj Kumar Verma (MK)

Institute of Endocrinology, Diabetes and Metabolism, Max Healthcare Institute Ltd., New Delhi.

Avijit Mazumder (A)

Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh.

Swati Waghdhare (S)

Institute of Endocrinology, Diabetes and Metabolism, Max Healthcare Institute Ltd, New Delhi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH